Pfizer on Tuesday reported $3.5 billion in first-quarter sales of its Covid-19 vaccine with German drugmaker BioNTech, APA reports citing CNBC.
In releasing its first-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.
Here’s how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted EPS: 93 cents per share vs 77 cents expected
- Revenue: $14.58 billion vs. $13.51 billion expected